Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017
(Thomson Reuters ONE) -
Conference call and webcast scheduled on 4:30pm ET
UTRECHT, The Netherlands, July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V.
(Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics (Biclonics®), today announced that the company
will provide an mid-year update on recent operating progress and report its
first quarter 2017 financial results on July 11, 2017. Management will host a
conference call and webcast at 4:30 pm ET.
To participate in the call, please dial (646) 722-4972 (domestic) or (866)
978-9968 (international) and reference conference ID 98331903. A live webcast
will be available on the Investors page of the Company's
website, http://www.merus.nl. An archived presentation will be available for 90
days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is expected to begin a Phase 2 clinical trial in the second
half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being
evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian,
endometrial and non-small cell lung cancers. Merus' second bispecific antibody
candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients
with acute myeloid leukemia. The Company also has a pipeline of proprietary
bispecific antibody candidates in preclinical development, including MCLA-158,
which is designed to bind to cancer stem cells and is being developed as a
potential treatment for colorectal cancer and other solid tumors, as well as
MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory
target, which is being developed in collaboration with Incyte.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 07.07.2017 - 17:52 Uhr
Sprache: Deutsch
News-ID 551477
Anzahl Zeichen: 2927
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 309 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
